NEWS

Tolerance Bio Advances into the Clinical Stage Through the Licensing of Efineptakin Alfa to Enhance Thymic Function and Improve Immune Resilience Read More
The CHMP Recommends Approval of the First Pharmacological Treatment for Cerebral Adrenoleukodystrophy Read More
$86.6 Million to Advance a New Generation of Therapies Against Treatment-Resistant Cancer Read More
Visium closes its first institutional funding round to accelerate AI adoption across the pharmaceutical and biotechnology industries, co-led by Columbus Venture Partners and Concentric Read More
Columbus Venture Partners drives the growth of Sermes CRO to strengthen clinical research in Spain and Europe Read More
Columbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S.-based Artis BioSolutions Read More
Accipiter Biosciences announces a $12.7M seed round to design protein therapies for complex diseases Read More
ARTHEx Biotech extends Series B to $87M to advance its therapy for Myotonic Dystrophy Type 1 Read More
Columbus Venture Partners increases its commitment to Integra Therapeutics with €10.7M raise Read More
Highlight Therapeutics and CNIO launch their seventh clinical trial in advanced skin cancer Read More
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness Read More
Quibim Announces a $50 Million Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers Read More
Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study Read More
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy Read More
Buenavista Equity Partners, together with Columbus Venture Partners, completes first €100mn closing for its healthcare fund Read More
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) Read More
Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer Read More
Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases  Read More
1 2 3 8
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.